<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04418453</url>
  </required_header>
  <id_info>
    <org_study_id>RMOUD1</org_study_id>
    <secondary_id>1UG1DA049435</secondary_id>
    <nct_id>NCT04418453</nct_id>
  </id_info>
  <brief_title>Rural MOUD Telemedicine in Primary Care Phase 1</brief_title>
  <acronym>Feasibility</acronym>
  <official_title>Rural Expansion of Medication Treatment for Opioid Use Disorder (Rural MOUD): Phase 1 Feasibility Study (CTN-0102)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The feasibility study (Phase 1) will examine the implementation of telemedicine (TM) in six
      rural clinics in two states/regions with varying levels of OBOT capacity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The dramatic increases in opioid overdose deaths across the nation, particularly in rural
      areas, call for a rapid expansion of access to medication treatment for opioid use disorder
      (MOUD).There is a need to study effective ways to expand treatment access and improve
      retention on MOUD in rural areas highly impacted by OUD. Telemedicine (TM) for MOUD offers an
      alternative or supplementary approach to delivering MOUD that may be suitable for rural
      clinics and patients with OUD.

      The objectives of the feasibility study are to study ways of incorporating TM into primary
      care clinics and to evaluate the associated outcomes, based on EHRs from the clinics and the
      TM vendor (i.e., patient days on MOUD) and participant surveys (e.g., opioid use). Additional
      outcomes of the feasibility study are feasibility and acceptability assessed from the
      perspectives of providers and participants via focus groups. A patient registry will be
      established in each clinic to track patients with OUD diagnoses, and those in the registry
      will be provided the opportunity to consent for sharing identified EHRs and participating in
      the follow-up surveys.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Patient days on MOUD from Electronic Health Records (EHR)</measure>
    <time_frame>9 months</time_frame>
    <description>Number of days patients receive MOUD based on EHR data</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of OUD patients initiating/receiving MOUD</measure>
    <time_frame>9 months</time_frame>
    <description>Number of OUD patients initiating/receiving MOUD</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Treatment retention</measure>
    <time_frame>3 months</time_frame>
    <description>Number of patients retained in treatment at 3 months post baseline</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">48000</enrollment>
  <condition>Opioid-use Disorder</condition>
  <arm_group>
    <arm_group_label>Integration of telemedicine in primary care settings for MOUD</arm_group_label>
    <description>Primary care providers may refer OUD patients to receive telemedicine for MOUD</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Integration of telemedicine for MOUD in primary care</intervention_name>
    <description>Patients with opioid use disorder in rural primary care settings may be referred to receive telemedicine for medication treatment for opioid use disorder</description>
    <arm_group_label>Integration of telemedicine in primary care settings for MOUD</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Primary care patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18-80 years old, inclusive, at the time of the qualifying visit

          -  with OUD diagnosis

          -  At least 1 visit to the participating clinics from 9 months before and 6 months after
             the date of intervention implementation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yih-Ing Hser, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yih-Ing Hser, Ph.D.</last_name>
    <phone>3102675289</phone>
    <email>yhser@mednet.ucla.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Larissa J Mooney, M.D.</last_name>
    <email>lmooney@mednet.ucla.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St. Mary's Hospital and Clinics</name>
      <address>
        <city>Cottonwood</city>
        <state>Idaho</state>
        <zip>83522</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Syringa Hospital and Clinics</name>
      <address>
        <city>Grangeville</city>
        <state>Idaho</state>
        <zip>83530</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penobscot Community Health Care</name>
      <address>
        <city>Belfast</city>
        <state>Maine</state>
        <zip>04915</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hometown Health Center</name>
      <address>
        <city>Dexter</city>
        <state>Maine</state>
        <zip>04930</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penobscot Community Health Care</name>
      <address>
        <city>Winterport</city>
        <state>Maine</state>
        <zip>04496</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Northeast Washington Medical Group</name>
      <address>
        <city>Colville</city>
        <state>Washington</state>
        <zip>99114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ferry County Health</name>
      <address>
        <city>Republic</city>
        <state>Washington</state>
        <zip>99166</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 21, 2020</study_first_submitted>
  <study_first_submitted_qc>June 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2020</study_first_posted>
  <last_update_submitted>June 3, 2020</last_update_submitted>
  <last_update_submitted_qc>June 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Yih-Ing Hser</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Medication treatment for opioid use disorder</keyword>
  <keyword>Telemedicine</keyword>
  <keyword>Rural areas</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The main dataset will be de-identified participant survey data and shared on the NIDA Data Share website.</ipd_description>
    <ipd_access_criteria>The data on NIDA Data Share website are accessible to anyone.</ipd_access_criteria>
    <ipd_url>https://datashare.nida.nih.gov/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

